For patients with advanced non-small cell lung cancer who showed an inadequate response to front-line immunotherapy checkpoint inhibitors and chemotherapy, the addition of CAN-2409 was well-tolerated.
The preliminary clinical data of CAN-2409, a replication-deficient adenoviral gene construct that delivers the thymidine kinase gene, was presented at ASCO Annual Meeting.